Nasdaq exas.

Oct 9, 2023 · MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ...

Nasdaq exas. Things To Know About Nasdaq exas.

If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Nov 1, 2023 · Exact Sciences Corp (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced on November 1, 2023, that the company generated revenue of $628.3 million for the third ... A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...

Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,859.47 +50.45(+2.79%) Crude Oil 74.22 -1.74(-2.29%) Gold 2,089.80 +32.60(+1.58%) Advertisement Exact Sciences Corporation …WebExact Sciences Co. (NASDAQ:EXAS – Free Report) – Equities researchers at William Blair increased their FY2023 earnings per share (EPS) estimates for Exact Sciences in a report released on ...

Oct 13, 2022 01:52PM EDT. Investors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the December 2nd expiration. At Stock Options Channel, our YieldBoost formula ...

Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. Shares of EXAS stock opened at $67.03 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.13 and a current ratio of 2.41. The firm has a market cap of $12.12 billion, a ...Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.Web

Dec 1, 2023 · On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...

May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...

Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...Exact Sciences Corp. (EXAS) has a Smart Score of 7 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge …WebEXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...1. Exact Sciences. Exact Sciences' goal is to eradicate cancer. Perhaps that's too optimistic, but the company could play a role in reducing cancer deaths through its diagnostic solutions.Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Notable Tuesday Option Activity: LTH, DECK, EXAS. January 10, 2023 — 03:23 pm EST. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...

Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...Dec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ... Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM ESTWebMADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...

Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...

Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Formed in 1995, Exact Sciences ( NASDAQ: EXAS) is a cancer screening and diagnostics company with the aim of early detection and improving cancer treatment. Currently, the company caters to ...Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Exact Sciences (EXAS) closed the most recent trading day at $65.41, moving +1.93% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.3%. Meanwhile, the Dow gained ...1. Exact Sciences Corp. (EXAS) In 2023, it is Exact Sciences that is the largest holding in Cathie Wood’s ARKK flagship ETF, and not Tesla. It is 9.7% of the portfolio. Exact Sciences has been ...

NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (0.14%) $0.09. ... 10 stocks we like better than Exact Sciences When o ur analyst team has a stock tip, ...

Nov 2, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. ... Exact Sciences (EXAS 4.73%) Q3 2023 Earnings Call Nov 01, 2023, 5:00 p.m. ET. Contents:

Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,859.47 +50.45(+2.79%) Crude Oil 74.22 -1.74(-2.29%) Gold 2,089.80 +32.60(+1.58%) Advertisement Exact Sciences Corporation …WebAmong the largest underlying components of ARKG, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.3%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 3%, and Intellia ...Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.77%. Meanwhile, the ...Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stockEXASNASDAQ See on Supercharts Overview News Ideas Financials Technicals Forecast EXAS chart Today 4.73% 5 days 2.38% 1 month 9.53% 6 months −21.08% Year to date …WebEDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... Analyst's Opinion · Consensus Rating. Exact Sciences has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to analysts' ...17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...Jul 31, 2023 · EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

See the latest Exact Sciences Corp stock price (EXAS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Dec 2, 2023 · Spyglass Capital Management LLC decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 36.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 661,930 shares of the medical research company's stock after selling 379,516 shares during the quarter. In the past 30 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has remained constant at $1.90 per share. The Zacks Consensus Estimate for 2023 revenues is pegged at $2.46 ...20 Okt 2023 ... PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...Instagram:https://instagram. stock with joshfkinx dividendupstart sotckgsat share price Jul 31, 2023 · EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ... Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.Web what is the worth of a kennedy half dollarpsychadelic etf 20 Okt 2023 ... PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... bnks "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...